Gene Editing Moved Lab-Grown Progeria Blood Vessels Back Toward Healthy Levels

The evidence is early. According to the study in Science Advances (2026), by Shores, Gao, Liu and Truskey, all the work was done in engineered blood vessels grown from human cells. No animals and no patients were involved. The excerpt of the paper available to us does not give the number of vessels tested, so we cannot report it.

The disease modelled is Hutchinson-Gilford progeria syndrome. It is rare and fatal. A single-letter change in the LMNA gene produces an abnormal protein called progerin. Progerin builds up in the cell nucleus and is linked to DNA repair problems and accelerated cell ageing. The paper says patients develop severe atherosclerosis, the hardening and narrowing of arteries, in their teenage years. In progeria this involves thickening of the vessel wall by scar-like tissue, inflammation and a loss of smooth muscle cells in the middle layer.

Most lab models of artery disease include only the inner lining cells and the smooth muscle cells. The authors point out that they leave out the outer layer, the adventitia, which is made mostly of fibroblasts. These cells control much of the vessel's structural matrix. The team made vessels with all three layers. They used stem-cellderived lining and smooth muscle cells plus skin fibroblasts, all from the same donor, and perfused the vessels with fluid for 10 days.

Adding fibroblasts made the vessels look more like real arteries. Gene activity in the three-layer vessels sat closer to that of 20 healthy human aorta and coronary artery samples from a public database. In progeria vessels, the fibroblasts increased matrix deposition, inflammation, stiffness and calcification, and lowered smooth muscle density. These are features of the disease. Two-layer vessels did not capture this to the same degree.

The team then used an adenine base editor to correct the LMNA mutation. The paper reports that reduced inflammation, less matrix build-up and higher smooth muscle density returned to the levels seen in vessels made from healthy donor cells. According to CRISPR Medicine News, the editor was delivered by a lentivirus. The outlet reports that it corrected 89 per cent of fibroblasts and at least 90 per cent of the vascular cells, and that calcification and stiffness also largely recovered. The outlet adds that the overall gene-activity pattern and the loss of tightly packed DNA, called heterochromatin, in fibroblasts persisted. So the repair was partial.

By mixing corrected and uncorrected cells, the authors also tested which cells matter most. Progerin-producing smooth muscle cells were the main contributors to smooth muscle loss, calcification and collagen build-up. Progerin-producing fibroblasts mainly affected a growth signal called TGF-beta-1 and the inflammatory molecule IL-6.

What does this mean for ordinary ageing? Calcification, stiffening and inflammation also affect the arteries of many older adults. The study offers a way to see which cell types drive these changes in progeria. But the paper modelled progeria only. It did not test normal ageing, so any link to everyday artery ageing is an inference, not a finding. The engineered vessels were also much softer than real coronary arteries. The paper gives their circumferential elastic modulus as 0.025 MPa, against 1.06 MPa for human coronary arteries of similar size.

Gene editing for age-related artery disease therefore remains a distant prospect. This was a rare single-gene disease in a dish. Common vascular ageing has many causes and has no single mutation to fix. Delivering an editor safely into a living person's arteries is a separate problem that this study did not address.

Watch next for tests of this approach in animal models of progeria and for studies using the same three-layer vessel to screen other therapies.